Solubility and stability of dalcetrapib in vehicles and biological media

International Journal of Pharmaceutics

Volumn 437, Issue 1-2, 2012, Pages 103-109

  Gross, Günter ^a   Tardio, Joseph ^a   Kuhlmann, Olaf ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Biological media; Biorelevant media; Cholesteryl ester transfer protein (CETP); Dalcetrapib; Dalcetrapib solubility; Dalcetrapib stability

Indexed keywords

1 METHYL 2 PYRROLIDINONE; 2 PROPANOL; ALCOHOL; DALCETRAPIB; GLYCEROL; MACROGOL 400; PROPYLENE GLYCOL; TRIACYLGLYCEROL LIPASE;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; IN VIVO STUDY; INTESTINE FLUID; PH; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; DRUG STABILITY; GASTRIC JUICE; HUMANS; INTESTINAL SECRETIONS; LECITHINS; LIPASE; SALIVA; SOLUBILITY; SOLVENTS; SULFHYDRYL COMPOUNDS; SURFACE-ACTIVE AGENTS;

EID: 84865425246     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.07.071     Document Type: Article

References (21)

1. D.B. Bentley, A.-M. Young, L. Rowell, G. Gross, J. Tardio, and D. Carlile Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat J Cardiovasc. Pharmacol 2012 [Epub ahead of print]
2. I.A. Brownlee, D.J. Forster, M.D. Wilcox, P.W. Dettmar, C.J. Seal, and J.P. Pearson Physiological parameters governing the action of pancreatic lipase Nutr. Res. Rev. 23 2010 146 154
3. H. Chahinian, T. Snabe, C. Attias, P. Fojan, S.B. Petersen, and F. Carrière How gastric lipase an interfacial enzyme with a Ser-His-Asp catalytic triad, acts optimally at acidic pH Biochemistry 45 2006 993 1001
4. 14C]-Dalcetrapib ADME following a single oral dose in healthy male subjects Clin. Pharmacol. Ther. 87 S37. 2010 (abstract)
5. M. Derks, H. Kawamura, M. Abt, G. Meneses-Lorente, M. Phelan, and T. Ishikawa Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers Clin. Ther. 33 2011 754 765
6. L. Di, and E.H. Kerns Solubility stability - plasma gastronintestinal, bioassay Curr. Drug Metab. 9 2008 860 868
7. M. Efentakis, and J.B. Dressman Gastric juice as a dissolution medium: surface tension and pH Eur. J. Drug Metab. Pharmacokinet. 23 1998 97 102
8. J.K. Embleton, and C.W. Poulton Structure and function of gastro-intestinal lipases Adv. Drug Deliv. Rev. 25 1997 15 32
9. T.D. Filippatos, C.S. Dermemexis, I.F. Gazi, E.S. Nakou, D.P. Mikhailidis, and M.S. Elisaf Orlistat-associated adverse effects and drug interactions. A critical review Drug Saf. 31 2008 53 65
10. Y. Finer, and J.P. Santerre Salivary esterase activity and its association with the biodegradation of dental composites J. Dent. Res. 83 2004 22 26
11. E. Galia, E. Nicolaides, D. Hörter, R. Löbenberg, C. Reppas, and J.B. Dressman Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 15 1998 698 705
12. K. Heinig, F. Bucheli, O. Kuhlmann, M. Zell, A. Pähler, E. Zwanziger, G. Gross, J. Tardio, T. Ishikawa, and T. Yamashita Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry J. Pharm. Biomed. Anal. 66 2012 314 324
13. O. Kuhlmann, and K. Heinig Dalcetrapib pharmacokinetics in the cynomolgus monkey Xenobiotica 41 2011 430 436
14. K. Matsuura, K. Murai, Y. Fukano, and H. Takashina Simultaneous determination of tiopronin and its metabolites in rat blood by LC-ESI-MS-MS using methyl acrylate for stabilization of thiol group J. Pharm. Biomed. Anal. 22 2000 101 109
15. S.D. Mithani, V. Bakatselou, C.N. TenHoor, and J.B. Dressman Estimation of the increase in solubility of drugs as a function of bile salt concentration Pharm. Res. 13 1996 163 167
16. E.M. Persson, A.-S. Gustafsson, A.S. Carlsson, R.G. Nilsson, L. Knutson, P. Forsell, G. Hanisch, H. Lennernäs, and B. Abrahamsson The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids Pharm. Res. 22 2005 2141 2151
17. T.L. Russell, R.R. Berardi, J.L. Barnett, L.C. Dermentzoglou, K.M. Jarvenpaa, S.P. Schmaltz, and J.B. Dressman Upper gastrointestinal pH in seventy-nine healthy elderly, North American men and women Pharm. Res. 10 1993 186 196
18. G.G. Schwartz, A.G. Olsson, C. Ballantyne, P.J. Barter, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J. McMurray, P.K. Shah, J.-C. Tardif, B.R. Chaitman, R. Duttlinger-Maddux, and J. Mathieson dal-OUTCOMES Committees and Investigators Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am. Heart J. 158 2009 896 901
19. M. Takahashi, H. Pang, K. Kawabata, N.A. Farid, and A. Kurihara Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS J. Pharm. Biomed. Anal. 48 2008 1219 1224
20. E.T. Williams, J.A. Bacon, D.M. Bender, J.J. Lowinger, W.K. Guo, M.E. Ehsani, X. Wang, H. Wang, Y.W. Qian, K.J. Ruterbories, S.A. Wrighton, and E.J. Perkins Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog cynomolgus monkey, and human Drug Metab. Dispos. 39 2011 2305 2313
21. D. Yang, R.E. Pearce, X. Wang, R. Gaedigk, Y.J. Wan, and B. Yan Human carboxylesterases HCE1 and HCE2: ontogenic expression inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin Biochem. Pharmacol. 77 2009 238 247